Is there room for a new way to drug RNA? ARCH, Fore­site join At­las, The Col­umn Group for $81M bet

By now, it ap­pears that drug hunters have ex­ploit­ed just about every ther­a­peu­tic an­gle hav­ing to do with RNA. Lever­ag­ing RNA as a ther­a­py? Check. Mak­ing an­ti­sense oligonu­cleotides that in­duce a par­tic­u­lar change? Check. Find­ing small mol­e­cules that bind to RNA, tar­get­ing the en­zymes that mod­i­fy it, or even cre­at­ing a way to ed­it it let­ter by let­ter? Check, check, check. But At­las and The Col­umn Group — both ac­tive in­vestors of those ef­forts — saw yet an­oth­er ap­proach to be tried.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER